Insmed (INSM)
(Delayed Data from NSDQ)
$25.00 USD
+0.20 (0.81%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $24.96 -0.04 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INSM 25.00 +0.20(0.81%)
Will INSM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for INSM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INSM
Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
INSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
Amgen (AMGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know
Other News for INSM
Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024
Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Roblox upgraded, Qualcomm initiated: Wall Street's top analyst calls
Roblox upgraded, Qualcomm initiated: Wall Street's top analyst calls
Analysts Conflicted on These Healthcare Names: Cartesian Therapeutics (RNAC), Insmed (INSM) and BioNTech SE (BNTX)